目的 探讨益胆胶囊联合熊去氧胆酸胶囊治疗肝内胆管结石的临床疗效。方法 选取沧州市中心医院2024年3月—2025年6月收治的110例肝内胆管结石患者，采用随机数字表法将患者分为对照组和治疗组，每组各55例。对照组温水送服熊去氧胆酸胶囊，1粒/次，3次/d。治疗组在对照组治疗基础上温水送服益胆胶囊，3粒/次，2次/d。两组均治疗6个月。比较两组临床疗效、肝功能指标、血清炎性因子、并发症和结石复发。结果 治疗组总有效率为94.5%，较对照组的80.0%高（P＜0.05）。治疗后两组碱性磷酸酶（ALP）、天冬氨酸氨基转氨酶（AST）、γ-谷氨酰转移酶（γ-GT）、丙氨酸氨基转移酶（ALT）均显著降低（P＜0.05），且治疗组ALP、AST、γ-GT、ALT低于对照组（P＜0.05）。两组治疗后血清肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、白细胞介素-8（IL-8）水平和中性粒细胞百分比（NEUT%）降低（P＜0.05），且治疗组血清TNF-α、IL-6、IL-8水平和NEUT%低于对照组（P＜0.05）。治疗组的并发症发生率、结石复发率低于对照组（P＜0.05）。结论 益胆胶囊联合熊去氧胆酸胶囊治疗肝内胆管结石可改善肝功能，抑制炎症反应，降低并发症和结石复发。

Objective To explore the clinical efficacy of Yidan Capsules combined with Ursodeoxycholic Acid Capsules in treatment of intrahepatic cholangiolar stones. Methods 110 Patients with intrahepatic cholangiolar stones admitted to Cangzhou Central Hospital from March 2024 to June 2025 were divided into control group and treatment group using a random number table method, with 55 patients in each group. The control group was administered with Ursodeoxycholic Acid Capsules with warm water, 1 capsule/time, 3 times daily. The treatment group was administered with Yidan Capsules with warm water on the basis of treatment in the control group, 3 capsules/time, twice daily. Two groups were treated for 6 months. The clinical efficacy, liver function indicators, serum inflammatory factors, complications, and stone recurrence were compared between two groups. Results The total effective rate of the treatment group was 94.5%, which was higher than the control group's 80.0% (P < 0.05). After treatment, the levels of alkaline phosphatase (ALP), aspartate aminotransferase (AST), gamma glutamyl transferase (γ-GT), and alanine aminotransferase (ALT) in two groups were significantly reduced (P < 0.05), and the ALP, AST, γ-GT, and ALT levels in the treatment group were lower than those in the control group (P < 0.05). After treatment, the serum levels of tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-8 (IL-8), and neutrophil percentage (NEUT%) decreased in two groups (P < 0.05), and the serum levels of TNF-α, IL-6, IL-8, and NEUT% in the treatment group were lower than those in the control group (P < 0.05). The incidence of complications and stone recurrence rate in the treatment group was lower than that in the control group (P < 0.05). Conclusion The combination of Yidan Capsules and Ursodeoxycholic Acid Capsules in treatment of intrahepatic cholangiolar stones can improve liver function, inhibit inflammatory response, and reduce the risk of complications and stone recurrence.

R975

河北省医学科学研究课题计划项目（20232113）